US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ATYR PHARMA INC

0.7520

-0.0407-5.13%

Post-market: 0.78330.0313+4.16%19:29 EDT

Volume:1.30M

Turnover:986.04K

Market Cap:73.69M

PE:-0.94

High:0.7927

Open:0.7758

Low:0.7500

Close:0.7927

52wk High:7.29

52wk Low:0.6400

Shares:97.99M

Float Shares:95.97M

Volume Ratio:1.35

T/O Rate:1.35%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7971

EPS(LYR):-0.7971

ROE:-108.11%

ROA:-51.12%

PB:1.09

PE(LYR):-0.94

Loading ...

Overview Company News Filings

aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call

aTyr Pharma Faces Investor Class Action Over Securities Fraud Allegations

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

aTyr Pharma Is Maintained at Sector Perform by RBC Capital

RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)

aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate

aTyr Pharma Inc reports results for the quarter ended September 30 - Earnings Summary

aTyr Pharma reports third quarter 2025 results and updates on efzofitimod studies

Press Release: aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Inc options imply 21.3% move in share price post-earnings

Calendar of U.S. Earnings Expected in the Week Ahead

aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call

Investors File Class Action Lawsuit Against aTyr Pharma Inc

aTyr Pharma (ATYR) Faces Legal Scrutiny After Failed Efzofitimod Trial - Can Its Credibility Recover?

Simply Wall St.

aTyr Pharma Inc. Director Paul Schimmel Reports Acquisition of Common Shares

aTyr Pharma reports clinical benefit for efzofitimod across multiple diseases

Piper Sandler healthcare analysts hold an analyst/industry conference call

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ATYR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATYR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","market":"US","secType":"STK","nameCN":"ATYR PHARMA INC","latestPrice":0.752,"timestamp":1774641600000,"preClose":0.7927,"halted":0,"volume":1299649,"hourTrading":{"tag":"盘后","latestPrice":0.7833,"preClose":0.752,"latestTime":"19:29 EDT","volume":9532,"amount":7207.4137,"timestamp":1774654159261,"change":0.0313,"changeRate":0.041622,"amplitude":0.041622},"delay":0,"changeRate":-0.05134350952441019,"floatShares":95966000,"shares":97986634,"eps":-0.797093,"marketStatus":"Market Closed","change":-0.0407,"latestTime":"03-27 16:00:00 EDT","open":0.7758,"high":0.7927,"low":0.75,"amount":986042.5266159,"amplitude":0.053867,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.797093,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1430971200000,"exchange":"NASDAQ","adjPreClose":0.7927,"preHourTrading":{"tag":"盘前","latestPrice":0.7815,"preClose":0.7927,"latestTime":"09:04 EDT","volume":2275,"amount":1780.6882275,"timestamp":1774616645023,"change":-0.0112,"changeRate":-0.014129,"amplitude":0.016021},"postHourTrading":{"tag":"盘后","latestPrice":0.7833,"preClose":0.752,"latestTime":"19:29 EDT","volume":9532,"amount":7207.4137,"timestamp":1774654159261,"change":0.0313,"changeRate":0.041622,"amplitude":0.041622},"volumeRatio":1.352,"impliedVol":1.7754,"impliedVolPercentile":0.5498},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATYR\",,,,,undefined,":{"symbol":"ATYR","floatShares":95966000,"roa":"-51.12%","roe":"-108.11%","lyrEps":-0.797093,"volumeRatio":1.352,"shares":97986634,"dividePrice":0,"high":0.7927,"amplitude":0.053867,"preClose":0.7927,"low":0.75,"week52Low":0.64,"pbRate":"1.09","psRate":"387.82","week52High":7.2904,"institutionHeld":0,"latestPrice":0.752,"eps":-0.797093,"divideRate":0,"volume":1299649,"delay":0,"ttmEps":-0.797093,"open":0.7758,"prevYearClose":0.7831,"prevWeekClose":0.8083,"prevMonthClose":0.9598,"prevQuarterClose":0.7831,"fiveDayClose":0.8083,"twentyDayClose":0.9598,"sixtyDayClose":0.745},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATYR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-05","symbol":"ATYR","fiscalQuarterEnding":"2025/12","expectedEps":-0.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.14},{"market":"US","date":"2025-11-06","symbol":"ATYR","fiscalQuarterEnding":"2025/09","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-08-07","symbol":"ATYR","fiscalQuarterEnding":"2025/06","expectedEps":-0.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2025-05-07","symbol":"ATYR","fiscalQuarterEnding":"2025/03","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":-0.17},{"market":"US","date":"2025-03-13","symbol":"ATYR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATYR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATYR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1,"buy":0.2,"hold":0.7,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7,"analysts":10,"updateTime":1762574400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATYR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATYR","date":"2026-03-27","current":-0.943428,"percent":0.877598,"low":-9.277729,"twenty":-5.203474,"median":-3.781997,"eighty":-1.214301,"high":-0.849664,"avg":-3.6342,"sd":2.289161,"marketCap":77725195},"quantilePoints":[{"date":"2024-06-07","current":-2.380173,"twenty":-2.380173,"median":-2.380173,"eighty":-2.380173,"marketCap":128360348},{"date":"2024-06-14","current":-2.367376,"twenty":-2.482546,"median":-2.431359,"eighty":-2.377614,"marketCap":127670239},{"date":"2024-06-21","current":-2.021867,"twenty":-2.446715,"median":-2.367376,"eighty":-2.203579,"marketCap":109037285},{"date":"2024-06-28","current":-1.970681,"twenty":-2.431359,"median":-2.367376,"eighty":-2.111444,"marketCap":106276847},{"date":"2024-07-05","current":-1.970681,"twenty":-2.431359,"median":-2.265003,"eighty":-1.991155,"marketCap":106276847},{"date":"2024-07-12","current":-2.073054,"twenty":-2.39041,"median":-2.092249,"eighty":-1.970681,"marketCap":111797722},{"date":"2024-07-15","current":-2.226613,"twenty":-2.380173,"median":-2.111444,"eighty":-1.970681,"marketCap":120079035},{"date":"2024-08-02","current":-2.495343,"twenty":-2.421122,"median":-2.130639,"eighty":-1.9758,"marketCap":134571333},{"date":"2024-08-09","current":-2.380173,"twenty":-2.403207,"median":-2.265003,"eighty":-1.996274,"marketCap":128360348},{"date":"2024-08-16","current":-2.618312,"twenty":-2.418704,"median":-2.296995,"eighty":-2.001393,"marketCap":151592396},{"date":"2024-08-23","current":-2.448121,"twenty":-2.445503,"median":-2.341783,"eighty":-2.021867,"marketCap":141738890},{"date":"2024-08-30","current":-2.474305,"twenty":-2.468042,"median":-2.373775,"eighty":-2.032104,"marketCap":143254814},{"date":"2024-09-06","current":-2.291023,"twenty":-2.461213,"median":-2.354579,"eighty":-2.073054,"marketCap":132643346},{"date":"2024-09-13","current":-2.448121,"twenty":-2.474305,"median":-2.380173,"eighty":-2.111444,"marketCap":141738890},{"date":"2024-09-20","current":-2.448121,"twenty":-2.474305,"median":-2.399368,"eighty":-2.149834,"marketCap":141738890},{"date":"2024-09-27","current":-2.277931,"twenty":-2.474305,"median":-2.382664,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-04","current":-2.277931,"twenty":-2.469749,"median":-2.373775,"eighty":-2.226613,"marketCap":131885384},{"date":"2024-10-11","current":-2.77541,"twenty":-2.474305,"median":-2.382664,"eighty":-2.251748,"marketCap":160687939},{"date":"2024-10-18","current":-3.469263,"twenty":-2.48085,"median":-2.399368,"eighty":-2.251748,"marketCap":200859924},{"date":"2024-10-25","current":-4.241665,"twenty":-2.500488,"median":-2.421938,"eighty":-2.265003,"marketCap":245579681},{"date":"2024-10-31","current":-4.097658,"twenty":-2.555472,"median":-2.431359,"eighty":-2.275241,"marketCap":237242099},{"date":"2024-11-08","current":-4.058383,"twenty":-2.922036,"median":-2.441575,"eighty":-2.277905,"marketCap":234968213},{"date":"2024-11-15","current":-3.78886,"twenty":-3.621287,"median":-2.448121,"eighty":-2.277931,"marketCap":241789871},{"date":"2024-11-22","current":-3.919838,"twenty":-3.629704,"median":-2.448121,"eighty":-2.277931,"marketCap":250148372},{"date":"2024-11-29","current":-4.643298,"twenty":-3.916561,"median":-2.461213,"eighty":-2.285786,"marketCap":296316696},{"date":"2024-12-06","current":-4.301299,"twenty":-4.007344,"median":-2.474305,"eighty":-2.298878,"marketCap":274491670},{"date":"2024-12-13","current":-3.972453,"twenty":-4.100191,"median":-2.474305,"eighty":-2.31136,"marketCap":253506069},{"date":"2024-12-20","current":-4.143453,"twenty":-4.111931,"median":-2.474305,"eighty":-2.3168,"marketCap":264418582},{"date":"2024-12-27","current":-4.95899,"twenty":-4.144489,"median":-2.487396,"eighty":-2.317206,"marketCap":316462874},{"date":"2025-01-03","current":-5.143143,"twenty":-4.229494,"median":-2.500488,"eighty":-2.317206,"marketCap":328214811},{"date":"2025-01-10","current":-4.919528,"twenty":-4.267848,"median":-2.526671,"eighty":-2.317206,"marketCap":313944602},{"date":"2025-01-17","current":-4.932682,"twenty":-4.327606,"median":-2.579037,"eighty":-2.328986,"marketCap":314784026},{"date":"2025-01-24","current":-4.682759,"twenty":-4.341161,"median":-2.768865,"eighty":-2.330035,"marketCap":298834968},{"date":"2025-01-31","current":-4.919528,"twenty":-4.389843,"median":-2.932509,"eighty":-2.330297,"marketCap":313944602},{"date":"2025-02-07","current":-5.090528,"twenty":-4.509129,"median":-3.510289,"eighty":-2.339486,"marketCap":324857115},{"date":"2025-02-14","current":-4.722221,"twenty":-4.606467,"median":-3.575068,"eighty":-2.341783,"marketCap":301353241},{"date":"2025-02-21","current":-5.827142,"twenty":-4.643298,"median":-3.6107,"eighty":-2.357139,"marketCap":371864863},{"date":"2025-02-28","current":-5.090528,"twenty":-4.682759,"median":-3.851618,"eighty":-2.375054,"marketCap":324857115},{"date":"2025-03-07","current":-4.051376,"twenty":-4.682759,"median":-3.972453,"eighty":-2.380173,"marketCap":258542613},{"date":"2025-03-14","current":-5.248373,"twenty":-4.682759,"median":-3.985607,"eighty":-2.381668,"marketCap":334930203},{"date":"2025-03-21","current":-4.929845,"twenty":-4.727483,"median":-3.990774,"eighty":-2.382664,"marketCap":315623450},{"date":"2025-03-28","current":-4.52461,"twenty":-4.75379,"median":-4.035211,"eighty":-2.388848,"marketCap":289679075},{"date":"2025-04-04","current":-3.872289,"twenty":-4.740636,"median":-4.038222,"eighty":-2.400648,"marketCap":247915527},{"date":"2025-04-11","current":-3.802893,"twenty":-4.727483,"median":-4.011134,"eighty":-2.407615,"marketCap":243472596},{"date":"2025-04-17","current":-4.191509,"twenty":-4.722221,"median":-4.035211,"eighty":-2.414083,"marketCap":268353008},{"date":"2025-04-25","current":-4.788314,"twenty":-4.743267,"median":-4.051376,"eighty":-2.421938,"marketCap":306562211},{"date":"2025-05-02","current":-4.635643,"twenty":-4.743267,"median":-4.087671,"eighty":-2.425706,"marketCap":296787764},{"date":"2025-05-09","current":-4.680309,"twenty":-4.75642,"median":-4.108234,"eighty":-2.431359,"marketCap":296787764},{"date":"2025-05-16","current":-4.210769,"twenty":-4.743267,"median":-4.133647,"eighty":-2.432827,"marketCap":267013308},{"date":"2025-05-23","current":-5.333641,"twenty":-4.774836,"median":-4.143453,"eighty":-2.440266,"marketCap":338216856},{"date":"2025-05-30","current":-5.972275,"twenty":-4.816072,"median":-4.149872,"eighty":-2.448121,"marketCap":378713875},{"date":"2025-06-06","current":-7.509205,"twenty":-4.87282,"median":-4.17922,"eighty":-2.448121,"marketCap":476173732},{"date":"2025-06-13","current":-7.621493,"twenty":-4.919528,"median":-4.191509,"eighty":-2.448121,"marketCap":483294087},{"date":"2025-06-20","current":-7.256559,"twenty":-4.932682,"median":-4.241665,"eighty":-2.448121,"marketCap":460152934},{"date":"2025-06-27","current":-7.453062,"twenty":-4.985297,"median":-4.254757,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-03","current":-7.453062,"twenty":-5.016231,"median":-4.28094,"eighty":-2.448121,"marketCap":472613555},{"date":"2025-07-11","current":-7.481134,"twenty":-5.080005,"median":-4.302543,"eighty":-2.458595,"marketCap":474393643},{"date":"2025-07-18","current":-8.126785,"twenty":-5.119466,"median":-4.327606,"eighty":-2.461213,"marketCap":515335684},{"date":"2025-07-25","current":-7.796941,"twenty":-5.18655,"median":-4.339852,"eighty":-2.468042,"marketCap":494419641},{"date":"2025-08-01","current":-6.624944,"twenty":-5.237851,"median":-4.345289,"eighty":-2.473394,"marketCap":420100937},{"date":"2025-08-08","current":-7.354811,"twenty":-5.277498,"median":-4.380221,"eighty":-2.474305,"marketCap":466383244},{"date":"2025-08-15","current":-7.337565,"twenty":-5.711388,"median":-4.396173,"eighty":-2.474305,"marketCap":488953303},{"date":"2025-08-22","current":-7.278747,"twenty":-6.338611,"median":-4.472298,"eighty":-2.474305,"marketCap":485033838},{"date":"2025-08-29","current":-7.866928,"twenty":-6.868599,"median":-4.491152,"eighty":-2.474305,"marketCap":524228491},{"date":"2025-09-05","current":-8.043383,"twenty":-7.051635,"median":-4.498606,"eighty":-2.474305,"marketCap":535986887},{"date":"2025-09-12","current":-7.734587,"twenty":-7.202339,"median":-4.538489,"eighty":-2.478232,"marketCap":515409694},{"date":"2025-09-19","current":-1.543977,"twenty":-7.202339,"median":-4.511608,"eighty":-2.474305,"marketCap":102885965},{"date":"2025-09-26","current":-1.313556,"twenty":-7.183573,"median":-4.496851,"eighty":-2.466335,"marketCap":87531460},{"date":"2025-10-03","current":-1.043875,"twenty":-7.138658,"median":-4.477635,"eighty":-2.448121,"marketCap":69560711},{"date":"2025-10-10","current":-1.401343,"twenty":-7.082514,"median":-4.406529,"eighty":-2.442885,"marketCap":93381262},{"date":"2025-10-17","current":-1.470454,"twenty":-7.051635,"median":-4.382946,"eighty":-2.421938,"marketCap":97986634},{"date":"2025-10-24","current":-1.430458,"twenty":-7.012335,"median":-4.346398,"eighty":-2.388848,"marketCap":95321397},{"date":"2025-10-31","current":-1.305763,"twenty":-6.956191,"median":-4.340306,"eighty":-2.375054,"marketCap":87012130},{"date":"2025-11-07","current":-1.004754,"twenty":-6.884883,"median":-4.327606,"eighty":-2.330297,"marketCap":75479104},{"date":"2025-11-14","current":-0.930535,"twenty":-6.741157,"median":-4.315074,"eighty":-2.317206,"marketCap":69903664},{"date":"2025-11-21","current":-0.849664,"twenty":-6.641787,"median":-4.294031,"eighty":-2.285786,"marketCap":63828493},{"date":"2025-11-28","current":-1.018058,"twenty":-6.613715,"median":-4.254757,"eighty":-2.277852,"marketCap":76478567},{"date":"2025-12-05","current":-1.079755,"twenty":-6.467742,"median":-4.247271,"eighty":-2.236667,"marketCap":81113335},{"date":"2025-12-12","current":-0.998232,"twenty":-6.153338,"median":-4.191509,"eighty":-2.08841,"marketCap":74989171},{"date":"2025-12-19","current":-0.9171,"twenty":-5.941396,"median":-4.17922,"eighty":-1.996274,"marketCap":68894402},{"date":"2025-12-26","current":-0.962753,"twenty":-5.88149,"median":-4.159816,"eighty":-1.970681,"marketCap":72323934},{"date":"2026-01-02","current":-1.02145,"twenty":-5.827142,"median":-4.144316,"eighty":-1.58809,"marketCap":76733333},{"date":"2026-01-09","current":-0.945796,"twenty":-5.68245,"median":-4.143453,"eighty":-1.529272,"marketCap":71050108},{"date":"2026-01-16","current":-0.921535,"twenty":-5.590373,"median":-4.115174,"eighty":-1.499863,"marketCap":69227556},{"date":"2026-01-23","current":-0.973579,"twenty":-5.463588,"median":-4.100824,"eighty":-1.470454,"marketCap":73137223},{"date":"2026-01-30","current":-1.109494,"twenty":-5.353291,"median":-4.058383,"eighty":-1.430928,"marketCap":83347430},{"date":"2026-02-06","current":-1.05745,"twenty":-5.277498,"median":-4.044799,"eighty":-1.420105,"marketCap":79437764},{"date":"2026-02-13","current":-1.16206,"twenty":-5.263462,"median":-4.025068,"eighty":-1.381433,"marketCap":87296292},{"date":"2026-02-20","current":-1.369585,"twenty":-5.259961,"median":-3.990774,"eighty":-1.302178,"marketCap":102885965},{"date":"2026-02-27","current":-1.291323,"twenty":-5.252075,"median":-3.985607,"eighty":-1.296092,"marketCap":97006767},{"date":"2026-03-06","current":-1.193659,"twenty":-5.240481,"median":-3.979834,"eighty":-1.286732,"marketCap":88471608},{"date":"2026-03-13","current":-1.147622,"twenty":-5.227328,"median":-3.937701,"eighty":-1.255818,"marketCap":85059426},{"date":"2026-03-20","current":-1.094838,"twenty":-5.211936,"median":-3.872289,"eighty":-1.237152,"marketCap":81147183},{"date":"2026-03-27","current":-1.048668,"twenty":-5.203474,"median":-3.781997,"eighty":-1.214301,"marketCap":77725195}],"updateTime":1774736426232},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATYR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583505010","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2583505010","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583505010?lang=en_us&edition=fundamental","pubTime":"2025-11-14 20:50","pubTimestamp":1763124618,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL5l4M05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2583414548","title":"aTyr Pharma Faces Investor Class Action Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2583414548","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583414548?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:45","pubTimestamp":1763073915,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 7, 2024 and September 12, 2025. The litigation claims that the company may have misled investors, prompting financial losses during this period. Levi & Korsinsky, a law firm specializing in securities litigation, is representing affected shareholders and encourages those impacted to seek more information about the case.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2DzGtj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"aTyr Pharma Faces Investor Class Action Over Securities Fraud Allegations","news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2582443879","title":"aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2582443879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582443879?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:02","pubTimestamp":1762779755,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York, NY. President and CEO Sanjay S. Shukla will participate in a fireside chat, and company management will be available for one-on-one meetings with investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on November 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL53g3Tx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4139","IE00BKPKM429.USD","LU0314104364.USD","BK4112","ATYR","IE00B64PRP62.GBP","LU2095319765.USD","PIPR","BK4588","BK4585","NDAQ","IE00BGHQF748.EUR","BK4127","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2581366898","title":"aTyr Pharma Is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581366898","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581366898?lang=en_us&edition=fundamental","pubTime":"2025-11-08 03:47","pubTimestamp":1762544820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATYR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2025 14:47 ET (19:47 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","LU0029864427.USD","BK4207","LU0128525929.USD","BK4139","LU1267930573.SGD","LU0708994859.HKD","LU0310800379.SGD"],"gpt_icon":0},{"id":"2581000287","title":"RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000287?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:37","pubTimestamp":1762519049,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on aTyr Pharma, with a price target of $1.00. The company’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-atyr-pharma-atyr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-sticks-to-its-hold-rating-for-atyr-pharma-atyr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR"],"gpt_icon":0},{"id":"2581463200","title":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581463200","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581463200?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:00","pubTimestamp":1762466444,"startTime":"0","endTime":"0","summary":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48706203/atyr-pharma-q3-eps-0-26-misses-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"aTyr Pharma Q3 EPS $(0.26) Misses $(0.18) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2581045415","title":"aTyr Pharma Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045415?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:51","pubTimestamp":1762465878,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc reports results for the quarter ended September 30 - Earnings SummaryaTyr Pharma Inc ATYR.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended September 30","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL8N3WI3TN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2581012792","title":"aTyr Pharma reports third quarter 2025 results and updates on efzofitimod studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012792","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012792?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462902,"startTime":"0","endTime":"0","summary":"aTyr Pharma Inc. reported cash, cash equivalents, restricted cash, and available-for-sale investments of $92.9 million as of September 30, 2025. Research and development expenses for the third quarter of 2025 were $22.1 million, primarily related to clinical trial and manufacturing costs for the efzofitimod program. General and administrative expenses were $4.8 million for the same period. During the quarter, aTyr Pharma announced results for the Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis and plans to meet with the FDA in the first quarter of 2026 to determine next steps. The company also expects to complete enrollment in the Phase 2 EFZO-CONNECT study in systemic sclerosis-related interstitial lung disease in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sho","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7lDkJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4588","BK4112","NDAQ","IE00B3QW5Z07.USD","ATYR","BK4139","BK4585","IE00BGHQF748.EUR","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2581201203","title":"Press Release: aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581201203","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581201203?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462860,"startTime":"0","endTime":"0","summary":"Results reported for Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis.Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.\"Based on the findings from EFZO-FIT, we believe there is drug activity for efzofitimod as evidenced by improvements across multiple clinically relevant efficacy measures. Based on this, coupled with the ongoing high unmet medical need in pulmonary sarcoidosis, we plan to meet with the U.S. Food and Drug Administration  in the first quarter of 2026 to review the results of the study and determine the path forward for efzofitimod in pulmonary sarcoidosis. We plan to provide an update regarding the next steps for the program following that meeting.\". Fatigue Assessment Scale, and complete steroid withdrawal and improvement","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4585","TM","BK4604","BK4588","BK4555","03160","BK4099","BK4139"],"gpt_icon":0},{"id":"2581811012","title":"aTyr Pharma Inc options imply 21.3% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2581811012","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581811012?lang=en_us&edition=fundamental","pubTime":"2025-11-07 04:35","pubTimestamp":1762461318,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 3:2. Implied volatility suggests the market is anticipating...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-21-3-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-inc-options-imply-21-3-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2581065756","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065756?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:00","pubTimestamp":1762426800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A-Mark Precs Mtl                                1Q       .60    4:05 PM. ·Achve Life Scncs                                3Q      (.24)   7:30 AM. ·Air Pdts and Chem                                4Q      3.38    6:00 AM. ·Alpha Metall Rsrcs                               3Q      (.52)   7:30 AM. ·Altice USA Inc.                                 3Q      (.06)   7:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASTH","ATYR","ABNB","ADVM","ATUS","BIOA","AMBQ","AMLX","APLT","CARL","ALRM","AMPX","GOOS","AMR","APD","ALTG","AMN","ACHV","BLZE","ACRV","AGO","AMTX","AMPH","AORT","ATHM","AURA","ABL","BIRD","ASPN","AFRM","ALG","ALLO","ACIW","ARHS","AVAH","OPTU","ATLC","ABCL","AEE","ADV","AAOI","AKAM","ARLO","ALT","AHR","ASMB","AMRK","APYX","APPN","AAON"],"gpt_icon":1},{"id":"2581472033","title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2581472033","media":"Reuters","labels":["policyRegulatory","dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581472033?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:05","pubTimestamp":1762347926,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL4ybXVq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"aTyr Pharma Reveals EFZO-FIT Study Failure in Investor Call","news_tag":"policyRegulatory,dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2577068928","title":"Investors File Class Action Lawsuit Against aTyr Pharma Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2577068928","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577068928?lang=en_us&edition=fundamental","pubTime":"2025-10-22 02:44","pubTimestamp":1761072256,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against aTyr Pharma Inc. on behalf of investors who suffered losses due to alleged securities fraud between January 16, 2025, and September 12, 2025. The legal action claims that shareholders were harmed by the company's conduct during this period. The law firm Levi & Korsinsky is leading the case, leveraging its extensive experience in complex securities litigation to represent affected investors. Shareholders who incurred losses have been encouraged to seek more information and consider participating in the lawsuit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 21, 2025, and is solely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDLc3gNGV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2574491904","title":"aTyr Pharma (ATYR) Faces Legal Scrutiny After Failed Efzofitimod Trial - Can Its Credibility Recover?","url":"https://stock-news.laohu8.com/highlight/detail?id=2574491904","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574491904?lang=en_us&edition=fundamental","pubTime":"2025-10-12 15:15","pubTimestamp":1760253333,"startTime":"0","endTime":"0","summary":"aTyr Pharma recently reported that its Phase 3 trial for efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint, leading to a wave of investor class action lawsuits alleging misleading statements about the drug’s efficacy.\nThere is significant investor scrutiny on the company’s prior disclosures and communications, as legal investigations focus on the statements made during the trial period.\nWe’ll examine how the trial failure and rising legal challenges may impact aTyr...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atyr/atyr-pharma/news/atyr-pharma-atyr-faces-legal-scrutiny-after-failed-efzofitim","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-atyr/atyr-pharma/news/atyr-pharma-atyr-faces-legal-scrutiny-after-failed-efzofitim","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2574663190","title":"aTyr Pharma Inc. Director Paul Schimmel Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574663190","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574663190?lang=en_us&edition=fundamental","pubTime":"2025-10-10 06:30","pubTimestamp":1760049058,"startTime":"0","endTime":"0","summary":"Paul Schimmel, Director at aTyr Pharma Inc., reported the acquisition of common shares of aTyr Pharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL764Fgd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"aTyr Pharma Inc. Director Paul Schimmel Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATYR"],"gpt_icon":0},{"id":"2571082345","title":"aTyr Pharma reports clinical benefit for efzofitimod across multiple diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2571082345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571082345?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:20","pubTimestamp":1759227648,"startTime":"0","endTime":"0","summary":"aTyr Pharma (ATYR) presented additional findings from the Phase 3 EFZO-FIT study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atyr-pharma-reports-clinical-benefit-for-efzofitimod-across-multiple-diseases-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atyr-pharma-reports-clinical-benefit-for-efzofitimod-across-multiple-diseases-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4139"],"gpt_icon":0},{"id":"2571681873","title":"Piper Sandler healthcare analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2571681873","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571681873?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:40","pubTimestamp":1759178408,"startTime":"0","endTime":"0","summary":"Healthcare Analysts discuss aTyr Pharma’s (ATYR) opportunity in Pulmonary Sarcoidosis on an Analyst/Industry conference call to be held on Septembe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/piper-sandler-healthcare-analysts-hold-an-analyst-industry-conference-call-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/piper-sandler-healthcare-analysts-hold-an-analyst-industry-conference-call-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATYR","BK4585","BK4139","XLV","BK4588","XBI","LABU","BK4581"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}]}}